Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Laurie Gaspar

Concepts (490)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Brain Neoplasms
101
2025
1329
5.940
 Why?
Lung Neoplasms
92
2025
2664
4.860
 Why?
Carcinoma, Non-Small-Cell Lung
54
2022
1189
3.810
 Why?
Radiosurgery
44
2022
399
3.590
 Why?
Cranial Irradiation
21
2025
85
2.770
 Why?
Small Cell Lung Carcinoma
12
2025
122
2.590
 Why?
Combined Modality Therapy
62
2022
1266
1.180
 Why?
Radiation Pneumonitis
5
2021
31
1.150
 Why?
Radiotherapy, Intensity-Modulated
9
2018
142
1.130
 Why?
Carcinoma, Small Cell
8
2007
172
1.060
 Why?
Antineoplastic Combined Chemotherapy Protocols
30
2023
1963
1.020
 Why?
Neoplasm Staging
39
2020
1471
1.000
 Why?
Radiotherapy Dosage
39
2023
288
0.980
 Why?
Chemoradiotherapy
8
2020
239
0.950
 Why?
Practice Guidelines as Topic
11
2021
1581
0.920
 Why?
Brachytherapy
12
2017
132
0.870
 Why?
Radiotherapy Planning, Computer-Assisted
11
2021
149
0.840
 Why?
Radiation Oncology
12
2022
82
0.810
 Why?
Glioblastoma
18
2016
353
0.800
 Why?
Neoplasm Recurrence, Local
21
2017
1149
0.790
 Why?
Adenocarcinoma
13
2022
925
0.680
 Why?
Glioma
15
2015
429
0.670
 Why?
Aged
103
2025
26153
0.650
 Why?
Esophageal Neoplasms
9
2008
348
0.640
 Why?
Survival Rate
31
2018
2090
0.640
 Why?
Liver Neoplasms
8
2009
776
0.640
 Why?
Prognosis
45
2022
4316
0.630
 Why?
Humans
222
2025
145474
0.630
 Why?
Radiotherapy, Conformal
8
2017
74
0.620
 Why?
Radiotherapy
14
2017
204
0.600
 Why?
Radiotherapy, Adjuvant
16
2022
222
0.600
 Why?
Clinical Trials as Topic
18
2018
1061
0.600
 Why?
Middle Aged
119
2025
36215
0.590
 Why?
Neurosurgeons
1
2019
17
0.580
 Why?
Dacarbazine
9
2016
100
0.580
 Why?
Evidence-Based Medicine
10
2021
740
0.570
 Why?
Four-Dimensional Computed Tomography
6
2021
38
0.550
 Why?
Oncologists
1
2018
47
0.510
 Why?
Carcinoma, Squamous Cell
10
2017
641
0.500
 Why?
Patient Selection
10
2019
738
0.500
 Why?
Cisplatin
18
2021
345
0.480
 Why?
Clinical Decision-Making
3
2021
363
0.480
 Why?
Male
129
2025
72842
0.470
 Why?
Aged, 80 and over
45
2020
8333
0.470
 Why?
Physician's Role
1
2018
223
0.470
 Why?
Antineoplastic Agents, Alkylating
8
2016
74
0.460
 Why?
Female
132
2025
78844
0.460
 Why?
Antineoplastic Agents
20
2017
2214
0.450
 Why?
Induction Chemotherapy
2
2013
88
0.430
 Why?
Adult
91
2025
40777
0.410
 Why?
Receptor Protein-Tyrosine Kinases
5
2017
231
0.410
 Why?
Survival Analysis
24
2020
1374
0.400
 Why?
Physician-Patient Relations
1
2018
588
0.380
 Why?
Treatment Outcome
36
2021
11772
0.370
 Why?
Etoposide
12
2021
168
0.370
 Why?
Pro-Opiomelanocortin
7
1989
20
0.350
 Why?
Pneumonectomy
2
2015
167
0.340
 Why?
Astrocytoma
9
2014
130
0.330
 Why?
Retrospective Studies
40
2022
17291
0.310
 Why?
Melanoma
5
2018
759
0.310
 Why?
Societies, Medical
7
2021
899
0.300
 Why?
Whole-Body Irradiation
1
2009
74
0.300
 Why?
Pulmonary Ventilation
4
2021
82
0.300
 Why?
Guidelines as Topic
2
2020
266
0.300
 Why?
Protein Kinase Inhibitors
4
2021
981
0.290
 Why?
Chemotherapy, Adjuvant
12
2017
423
0.290
 Why?
Karnofsky Performance Status
11
2020
37
0.290
 Why?
ErbB Receptors
8
2022
635
0.290
 Why?
Guideline Adherence
4
2018
586
0.290
 Why?
Medical Oncology
7
2021
339
0.280
 Why?
Quinazolines
6
2014
266
0.280
 Why?
Dose-Response Relationship, Radiation
11
2019
140
0.280
 Why?
Iodine Radioisotopes
6
2006
136
0.270
 Why?
Lung
9
2021
4106
0.270
 Why?
Breast Neoplasms
9
2020
2382
0.270
 Why?
Re-Irradiation
2
2018
9
0.260
 Why?
Controlled Clinical Trials as Topic
1
2007
27
0.260
 Why?
Neoplasm Metastasis
8
2019
688
0.260
 Why?
Radiopharmaceuticals
5
2014
205
0.260
 Why?
Disease Progression
13
2018
2864
0.260
 Why?
Follow-Up Studies
22
2018
5423
0.250
 Why?
Anticonvulsants
2
2019
246
0.240
 Why?
Tumor Burden
9
2017
325
0.240
 Why?
Biomarkers, Tumor
6
2021
1321
0.230
 Why?
Paclitaxel
5
2011
257
0.230
 Why?
Proto-Oncogene Proteins B-raf
2
2017
223
0.220
 Why?
Tomography, X-Ray Computed
10
2018
2769
0.220
 Why?
Prospective Studies
22
2018
8057
0.220
 Why?
Spinal Cord
4
2018
382
0.220
 Why?
Steroids
2
2019
160
0.210
 Why?
Taxoids
5
2015
114
0.210
 Why?
Carcinoma
1
2006
225
0.200
 Why?
Lymphatic Metastasis
3
2017
331
0.200
 Why?
Central Nervous System
2
2017
282
0.200
 Why?
Gastrointestinal Neoplasms
3
2019
73
0.190
 Why?
Carcinoma, Renal Cell
3
2018
230
0.190
 Why?
Carcinoma, Hepatocellular
2
2005
372
0.190
 Why?
Magnetic Resonance Imaging
9
2019
3904
0.190
 Why?
Radiography
8
2014
852
0.180
 Why?
Necrosis
3
2019
244
0.180
 Why?
Medical Illustration
2
2012
10
0.180
 Why?
Randomized Controlled Trials as Topic
7
2021
1747
0.170
 Why?
Organs at Risk
2
2012
37
0.170
 Why?
Ribs
2
2012
35
0.170
 Why?
Positron Emission Tomography Computed Tomography
2
2020
117
0.170
 Why?
Brachial Plexus
2
2012
34
0.170
 Why?
Professional Staff Committees
4
2001
10
0.170
 Why?
Oligodendroglioma
4
2014
15
0.160
 Why?
Esophagectomy
1
2002
135
0.160
 Why?
Testicular Neoplasms
1
2022
111
0.160
 Why?
Neoplasms
6
2020
2906
0.160
 Why?
Mutation
4
2021
4075
0.160
 Why?
Peptide Fragments
4
1989
693
0.160
 Why?
Research Design
7
2018
1137
0.150
 Why?
Proportional Hazards Models
8
2020
1327
0.150
 Why?
Metalloporphyrins
3
2011
63
0.150
 Why?
Thymoma
2
2017
37
0.150
 Why?
Thymus Neoplasms
2
2017
30
0.150
 Why?
Hippocampus
1
2025
971
0.150
 Why?
Consolidation Chemotherapy
1
2019
11
0.150
 Why?
Esophagus
2
2012
262
0.150
 Why?
Maximum Tolerated Dose
6
2010
210
0.150
 Why?
Meningeal Neoplasms
3
2017
95
0.150
 Why?
Congresses as Topic
2
2019
223
0.150
 Why?
Time Factors
10
2019
7123
0.140
 Why?
Quality of Life
6
2025
3204
0.140
 Why?
Radiation Injuries
5
2015
149
0.140
 Why?
Expert Testimony
1
2019
42
0.140
 Why?
Watchful Waiting
1
2019
90
0.140
 Why?
Aquaporin 4
1
2019
101
0.140
 Why?
Gray Matter
1
2019
92
0.140
 Why?
Intracranial Arteriovenous Malformations
2
1995
53
0.130
 Why?
Spinal Neoplasms
1
2018
37
0.130
 Why?
CTLA-4 Antigen
1
2018
105
0.130
 Why?
Carboplatin
4
2011
162
0.130
 Why?
Intersectoral Collaboration
1
2018
64
0.130
 Why?
Endpoint Determination
1
2018
85
0.130
 Why?
Treatment Failure
5
2014
360
0.130
 Why?
Kidney Neoplasms
3
2018
413
0.130
 Why?
Professional Competence
1
2018
91
0.130
 Why?
Cognition
4
2013
1266
0.130
 Why?
Genes, ras
1
2017
96
0.130
 Why?
Decision Trees
1
1997
78
0.120
 Why?
Triazines
2
2009
49
0.120
 Why?
Pituitary Neoplasms
5
1994
190
0.120
 Why?
Proto-Oncogene Proteins c-kit
1
2017
72
0.120
 Why?
Antineoplastic Agents, Immunological
1
2019
198
0.120
 Why?
Interdisciplinary Communication
1
2018
200
0.120
 Why?
Mortality
1
2019
378
0.120
 Why?
Hemangioma, Cavernous
2
1993
13
0.120
 Why?
Fluorouracil
6
2004
231
0.120
 Why?
Brain
5
2019
2947
0.120
 Why?
Salvage Therapy
4
2017
165
0.120
 Why?
Programmed Cell Death 1 Receptor
1
2018
265
0.120
 Why?
Antibodies
1
2018
397
0.120
 Why?
Pulmonary Atelectasis
1
2015
15
0.120
 Why?
Cohort Studies
7
2019
6013
0.120
 Why?
Age Factors
8
2017
3342
0.120
 Why?
Adrenal Cortex Hormones
1
2019
484
0.110
 Why?
Accreditation
2
2013
101
0.110
 Why?
Patient Preference
1
2018
223
0.110
 Why?
Radiation-Sensitizing Agents
5
2009
43
0.110
 Why?
Medically Underserved Area
1
2016
100
0.110
 Why?
Antineoplastic Agents, Phytogenic
2
2006
178
0.110
 Why?
Radiographic Image Interpretation, Computer-Assisted
1
2015
122
0.110
 Why?
Postoperative Care
1
2017
286
0.110
 Why?
United States
13
2022
16098
0.110
 Why?
Central Nervous System Neoplasms
1
2017
177
0.110
 Why?
Receptors, Progesterone
4
2020
243
0.100
 Why?
Carmustine
7
2010
52
0.100
 Why?
Analysis of Variance
5
2014
1300
0.100
 Why?
Perfusion Imaging
1
2014
66
0.100
 Why?
Fibrosarcoma
1
1993
23
0.100
 Why?
Lymphoma, Large-Cell, Anaplastic
1
2014
22
0.100
 Why?
Camptothecin
2
2011
138
0.100
 Why?
Triple Negative Breast Neoplasms
1
2017
218
0.100
 Why?
Risk Assessment
3
2021
3747
0.100
 Why?
Contraindications
2
2008
90
0.100
 Why?
Nelson Syndrome
4
1987
5
0.100
 Why?
Cerebellar Neoplasms
2
1996
177
0.100
 Why?
Medulloblastoma
2
1996
215
0.100
 Why?
Adolescent
22
2017
22529
0.100
 Why?
Respiratory Function Tests
1
2015
544
0.100
 Why?
Kaplan-Meier Estimate
5
2019
969
0.090
 Why?
Disease-Free Survival
6
2014
767
0.090
 Why?
Gene Expression Regulation, Neoplastic
1
2019
1443
0.090
 Why?
Pyrazoles
2
2014
517
0.090
 Why?
beta-Endorphin
3
1989
4
0.090
 Why?
Pyridines
2
2014
609
0.090
 Why?
Radiotherapy, High-Energy
4
2000
18
0.090
 Why?
Particle Accelerators
1
1991
9
0.090
 Why?
Adrenocorticotropic Hormone
3
1989
147
0.090
 Why?
Bone Neoplasms
3
2007
259
0.080
 Why?
Pancreatic Neoplasms
1
2000
928
0.080
 Why?
Forced Expiratory Volume
2
2015
450
0.080
 Why?
Radiation Protection
2
2009
41
0.080
 Why?
Quality Assurance, Health Care
3
2009
342
0.080
 Why?
Hyperthermia, Induced
1
1992
120
0.080
 Why?
Young Adult
8
2017
14218
0.080
 Why?
Technology, Radiologic
1
2010
6
0.080
 Why?
Radiotherapy, Computer-Assisted
1
2010
12
0.080
 Why?
Bevacizumab
3
2015
168
0.080
 Why?
MEDLINE
1
2009
20
0.080
 Why?
Databases, Factual
5
2017
1490
0.080
 Why?
Spine
1
1991
182
0.080
 Why?
Clinical Trials, Phase II as Topic
2
2002
75
0.080
 Why?
Neurosurgery
1
2009
41
0.080
 Why?
Multivariate Analysis
6
2020
1547
0.070
 Why?
Severity of Illness Index
2
2008
2930
0.070
 Why?
Adenoma
4
1994
218
0.070
 Why?
Adrenal Medulla
1
1989
10
0.070
 Why?
Neurotensin
1
1989
14
0.070
 Why?
Drug Therapy
1
2009
84
0.070
 Why?
Piperidines
1
2010
222
0.070
 Why?
Fractures, Spontaneous
1
1988
15
0.070
 Why?
Risk Factors
7
2021
10885
0.070
 Why?
Meta-Analysis as Topic
1
2009
171
0.070
 Why?
Ependymoma
2
2009
176
0.070
 Why?
Catheter Ablation
1
2012
355
0.070
 Why?
Esophageal Fistula
2
2000
21
0.070
 Why?
Equipment Failure Analysis
1
2009
124
0.070
 Why?
Imaging, Three-Dimensional
2
2010
583
0.070
 Why?
Liver
2
2008
1896
0.070
 Why?
Humeral Fractures
1
1988
46
0.070
 Why?
Pheochromocytoma
1
1989
67
0.070
 Why?
Radionuclide Imaging
1
2008
115
0.070
 Why?
Education, Medical, Graduate
1
2013
562
0.070
 Why?
Respiratory Mechanics
1
2008
74
0.070
 Why?
Lymph Node Excision
1
2009
173
0.070
 Why?
Adrenal Gland Neoplasms
1
1989
98
0.070
 Why?
Femoral Fractures
1
1988
84
0.070
 Why?
Craniopharyngioma
1
2009
77
0.070
 Why?
Positron-Emission Tomography
2
2008
343
0.070
 Why?
Chromatography, Gel
4
1989
130
0.070
 Why?
Pulmonary Disease, Chronic Obstructive
1
2015
919
0.060
 Why?
Palliative Care
5
2018
1020
0.060
 Why?
Surveys and Questionnaires
2
2018
6066
0.060
 Why?
Kidney
2
2005
1497
0.060
 Why?
Statistics, Nonparametric
2
2018
428
0.060
 Why?
Radioimmunoassay
4
1989
165
0.060
 Why?
Vascular Diseases
1
2009
252
0.060
 Why?
Genetic Markers
2
2017
335
0.060
 Why?
Whole Body Imaging
1
2006
29
0.060
 Why?
Uterine Cervical Neoplasms
1
1989
268
0.060
 Why?
Biomedical Research
2
2009
717
0.060
 Why?
Hepatitis B, Chronic
1
2005
22
0.060
 Why?
Neoplasm Grading
2
2020
310
0.060
 Why?
Linear Models
3
2017
845
0.060
 Why?
Drug Administration Schedule
3
2014
782
0.060
 Why?
Strontium Radioisotopes
2
2006
3
0.060
 Why?
Vascular Endothelial Growth Factor A
1
2008
552
0.060
 Why?
Seizures
1
2009
483
0.060
 Why?
Diagnostic Imaging
3
2009
337
0.060
 Why?
Databases as Topic
1
2005
71
0.060
 Why?
Gene Rearrangement
2
2018
155
0.060
 Why?
Delivery of Health Care
1
2012
946
0.060
 Why?
Consensus
2
2021
477
0.050
 Why?
Clinical Competence
1
2013
1243
0.050
 Why?
Antiemetics
1
2005
51
0.050
 Why?
Hemoglobins
1
2007
386
0.050
 Why?
Pituitary Hormones
1
1984
15
0.050
 Why?
Organ Size
1
2005
461
0.050
 Why?
Peptides
3
1985
998
0.050
 Why?
Immunotherapy
2
2022
666
0.050
 Why?
Body Fluids
1
1985
71
0.050
 Why?
Physicians
1
2013
955
0.050
 Why?
Retreatment
3
2012
79
0.050
 Why?
Cognition Disorders
2
2010
541
0.050
 Why?
Dexamethasone
3
2012
365
0.050
 Why?
Age Distribution
1
2005
403
0.050
 Why?
Sex Distribution
1
2005
387
0.050
 Why?
Anticoagulants
1
2009
748
0.050
 Why?
Practice Patterns, Physicians'
1
2013
1371
0.050
 Why?
Regression Analysis
2
2017
1001
0.050
 Why?
Hepatitis C, Chronic
1
2005
153
0.050
 Why?
Erlotinib Hydrochloride
2
2014
72
0.050
 Why?
Liver Cirrhosis
1
2005
287
0.050
 Why?
Feasibility Studies
3
2011
1111
0.050
 Why?
Propionates
1
2003
39
0.050
 Why?
Drug-Related Side Effects and Adverse Reactions
1
2006
261
0.050
 Why?
Chromatography, Affinity
3
1989
80
0.050
 Why?
Preoperative Care
1
2005
380
0.050
 Why?
Internship and Residency
1
2013
1267
0.050
 Why?
Aniline Compounds
1
2003
120
0.050
 Why?
Societies
1
2022
40
0.050
 Why?
Clinical Trials, Phase III as Topic
2
2004
116
0.040
 Why?
Pterygium
1
2000
4
0.040
 Why?
Organizational Objectives
4
2001
67
0.040
 Why?
Algorithms
2
2017
1845
0.040
 Why?
Ontario
2
2017
90
0.040
 Why?
Esophagoscopy
1
2002
223
0.040
 Why?
Reproducibility of Results
2
2015
3413
0.040
 Why?
Neurologic Examination
1
2000
132
0.040
 Why?
Vincristine
2
2010
142
0.040
 Why?
B7-H1 Antigen
1
2022
244
0.040
 Why?
BRCA1 Protein
1
2020
82
0.040
 Why?
Carcinoma, Bronchogenic
1
1999
20
0.040
 Why?
Spinal Cord Neoplasms
1
1999
41
0.040
 Why?
Receptors, Estrogen
2
2013
401
0.040
 Why?
Carcinoma, Large Cell
1
1999
17
0.040
 Why?
Neuropsychological Tests
3
2013
1134
0.040
 Why?
Medical Records
2
2010
192
0.040
 Why?
Liver Transplantation
1
2005
826
0.030
 Why?
Reoperation
2
2012
633
0.030
 Why?
Estrogens
1
2020
367
0.030
 Why?
Urinary Bladder Neoplasms
1
2001
258
0.030
 Why?
Thoracic Vertebrae
1
2018
82
0.030
 Why?
Iridium Radioisotopes
1
1997
4
0.030
 Why?
Epidemiologic Methods
1
2017
91
0.030
 Why?
Aziridines
2
1994
6
0.030
 Why?
Clinical Trials, Phase I as Topic
1
1997
50
0.030
 Why?
Colorado
3
2014
4553
0.030
 Why?
Child, Preschool
7
2009
11853
0.030
 Why?
Skin Neoplasms
2
2017
849
0.030
 Why?
Molecular Weight
2
1989
312
0.030
 Why?
Biopsy, Needle
1
2017
185
0.030
 Why?
Benzoquinones
2
1994
46
0.030
 Why?
Esophagitis
2
2009
67
0.030
 Why?
Respiration
1
2017
206
0.030
 Why?
Memory Disorders
2
2010
197
0.030
 Why?
Supratentorial Neoplasms
1
1996
18
0.030
 Why?
Neutropenia
2
2009
154
0.030
 Why?
Odds Ratio
1
1999
1082
0.030
 Why?
Precision Medicine
1
2020
459
0.030
 Why?
Heart
1
2020
626
0.030
 Why?
Meningioma
1
1997
88
0.030
 Why?
Propensity Score
1
2018
377
0.030
 Why?
Estrogen Receptor alpha
1
2017
151
0.030
 Why?
Sex Factors
2
2014
2105
0.030
 Why?
Cerebral Angiography
1
1995
119
0.030
 Why?
Forecasting
3
2001
390
0.030
 Why?
Marital Status
1
2014
46
0.030
 Why?
Pilot Projects
3
2015
1891
0.030
 Why?
Myocardium
1
2020
934
0.030
 Why?
Technetium Tc 99m Pentetate
1
2014
7
0.030
 Why?
Ventilation-Perfusion Ratio
1
2014
11
0.030
 Why?
Nuclear Medicine
1
2014
9
0.030
 Why?
Vital Capacity
1
2015
292
0.030
 Why?
Radioisotope Teletherapy
1
1993
2
0.030
 Why?
Cobalt Radioisotopes
1
1993
7
0.030
 Why?
Molecular Targeted Therapy
1
2017
439
0.030
 Why?
Nervous System Diseases
1
1997
286
0.030
 Why?
Patient Safety
1
2017
356
0.020
 Why?
Texas
1
2014
272
0.020
 Why?
Spatial Analysis
1
2013
21
0.020
 Why?
Child
9
2009
22707
0.020
 Why?
SEER Program
1
2014
229
0.020
 Why?
Vimentin
1
1993
54
0.020
 Why?
Radiodermatitis
1
1993
11
0.020
 Why?
Prostatic Neoplasms
1
2001
978
0.020
 Why?
Developing Countries
1
2016
316
0.020
 Why?
Radiometry
1
2013
56
0.020
 Why?
Monte Carlo Method
1
2013
147
0.020
 Why?
Observer Variation
1
2014
357
0.020
 Why?
Scalp
1
1993
38
0.020
 Why?
Protein-Tyrosine Kinases
1
2016
431
0.020
 Why?
Cerebral Cortex
1
1996
473
0.020
 Why?
Time
1
2013
84
0.020
 Why?
Mitosis
1
1993
193
0.020
 Why?
Medical Errors
1
2013
119
0.020
 Why?
Radiation Dosage
1
2013
193
0.020
 Why?
Remission Induction
2
2008
307
0.020
 Why?
Ascorbic Acid
1
1993
184
0.020
 Why?
Radiology
1
2014
174
0.020
 Why?
Disease Management
1
2016
653
0.020
 Why?
International Agencies
1
2011
30
0.020
 Why?
Diagnosis, Differential
1
2015
1508
0.020
 Why?
Breast Neoplasms, Male
1
2011
29
0.020
 Why?
Electrons
1
1991
80
0.020
 Why?
Bronchography
1
2010
10
0.020
 Why?
Fibrosis
1
2013
559
0.020
 Why?
Sensitivity and Specificity
1
2015
1997
0.020
 Why?
Infusions, Intravenous
2
2004
428
0.020
 Why?
Procarbazine
1
1990
9
0.020
 Why?
Lomustine
1
1990
17
0.020
 Why?
Longitudinal Studies
1
2018
2953
0.020
 Why?
Cell Nucleus
1
1993
588
0.020
 Why?
Physics
1
2010
17
0.020
 Why?
Smoking
1
2017
1472
0.020
 Why?
Selection Bias
1
2009
38
0.020
 Why?
Clinical Trials Data Monitoring Committees
1
2009
3
0.020
 Why?
Neoplasm, Residual
1
2010
143
0.020
 Why?
Hypophysectomy
1
1989
12
0.020
 Why?
Quality Control
1
2010
161
0.020
 Why?
Immunohistochemistry
1
1993
1716
0.020
 Why?
Chromatin
1
1993
553
0.020
 Why?
Platinum
1
2009
48
0.020
 Why?
Incidence
1
2016
2923
0.020
 Why?
Adrenal Cortex
1
1989
33
0.020
 Why?
Prevalence
1
2016
2865
0.020
 Why?
Hepatic Veno-Occlusive Disease
1
2008
12
0.020
 Why?
Bronchi
1
2010
263
0.020
 Why?
Neoplasms, Unknown Primary
1
1988
20
0.020
 Why?
Prostheses and Implants
1
2010
137
0.020
 Why?
Polymorphism, Single Nucleotide
1
2016
2158
0.020
 Why?
beta-Lipotropin
2
1985
2
0.020
 Why?
Liver Regeneration
1
2008
46
0.020
 Why?
Certification
1
2010
119
0.020
 Why?
Endorphins
2
1985
9
0.020
 Why?
Anti-Inflammatory Agents
1
2012
477
0.020
 Why?
Epinephrine
1
1989
158
0.020
 Why?
Motion
1
2008
94
0.020
 Why?
Fracture Fixation, Intramedullary
1
1988
60
0.020
 Why?
International Cooperation
1
2008
197
0.020
 Why?
Administration, Oral
1
2010
866
0.020
 Why?
Mental Status Schedule
1
2007
35
0.020
 Why?
Reference Values
1
1989
798
0.020
 Why?
Genetic Predisposition to Disease
1
2016
2378
0.020
 Why?
Infant
4
1999
10077
0.020
 Why?
Creatinine
1
1989
515
0.020
 Why?
Bleomycin
1
2009
255
0.020
 Why?
Rectal Neoplasms
1
2008
159
0.020
 Why?
Predictive Value of Tests
2
2008
2121
0.020
 Why?
Chromatography, High Pressure Liquid
1
1989
592
0.020
 Why?
Southwestern United States
1
2006
93
0.020
 Why?
California
1
2008
471
0.020
 Why?
Neovascularization, Pathologic
1
2008
286
0.020
 Why?
Chromium Compounds
1
2006
2
0.010
 Why?
Glucocorticoids
1
2010
531
0.010
 Why?
Polycythemia Vera
1
2006
8
0.010
 Why?
Hydrocephalus
1
1987
111
0.010
 Why?
Pleural Effusion, Malignant
1
2006
12
0.010
 Why?
Sodium Iodide
1
2006
4
0.010
 Why?
Hyperthyroidism
1
2006
22
0.010
 Why?
Patient Isolation
1
2006
20
0.010
 Why?
Ascites
1
2006
48
0.010
 Why?
Yttrium Radioisotopes
1
2006
63
0.010
 Why?
DNA Repair
1
2008
254
0.010
 Why?
Methadone
1
1987
122
0.010
 Why?
DNA Damage
1
2008
437
0.010
 Why?
Chromatography
1
1985
27
0.010
 Why?
Concanavalin A
1
1985
72
0.010
 Why?
Organophosphorus Compounds
1
2006
84
0.010
 Why?
Phosphates
1
2006
177
0.010
 Why?
ACTH Syndrome, Ectopic
1
1984
1
0.010
 Why?
Occipital Lobe
1
2004
26
0.010
 Why?
Organometallic Compounds
1
2006
113
0.010
 Why?
Lymphoma, Non-Hodgkin
1
2006
124
0.010
 Why?
Biotransformation
1
1984
62
0.010
 Why?
Patient Education as Topic
1
2010
777
0.010
 Why?
Brain Edema
1
2004
62
0.010
 Why?
Carbohydrate Metabolism
1
1984
59
0.010
 Why?
Thrombocytopenia
1
2006
204
0.010
 Why?
Arginine Vasopressin
1
1984
44
0.010
 Why?
Genomics
1
2009
825
0.010
 Why?
Recurrence
2
2000
1138
0.010
 Why?
Vomiting
1
2004
131
0.010
 Why?
Corticotropin-Releasing Hormone
1
1984
72
0.010
 Why?
Oils
1
1983
22
0.010
 Why?
Motor Skills
1
2004
104
0.010
 Why?
Bipolar Disorder
1
1985
282
0.010
 Why?
Thyroid Neoplasms
1
2006
350
0.010
 Why?
Immunologic Factors
1
2003
260
0.010
 Why?
Antimetabolites, Antineoplastic
1
2001
106
0.010
 Why?
Pain
1
2006
789
0.010
 Why?
Psychometrics
1
2004
731
0.010
 Why?
Postoperative Period
1
2000
351
0.010
 Why?
Apoptosis
1
2008
2440
0.010
 Why?
Thorax
1
1999
51
0.010
 Why?
Michigan
1
1999
134
0.010
 Why?
Opioid-Related Disorders
1
1987
602
0.010
 Why?
Bias
1
1999
197
0.010
 Why?
Cysts
1
1999
112
0.010
 Why?
Antibodies, Monoclonal
1
2006
1505
0.010
 Why?
Mercaptopurine
1
1996
15
0.010
 Why?
Mitomycin
1
1996
32
0.010
 Why?
Meninges
1
1997
49
0.010
 Why?
Biopsy
1
1999
1082
0.010
 Why?
Cross-Sectional Studies
1
2007
5904
0.010
 Why?
Autoantibodies
1
1983
1509
0.010
 Why?
Cause of Death
1
1996
470
0.010
 Why?
Decision Making
1
2001
977
0.010
 Why?
Solutions
1
1993
159
0.010
 Why?
Neoplasms, Radiation-Induced
1
1993
100
0.010
 Why?
Cerebral Hemorrhage
1
1993
125
0.010
 Why?
Computer Simulation
1
1995
1003
0.010
 Why?
Patient Compliance
1
1994
587
0.000
 Why?
Evaluation Studies as Topic
1
1989
164
0.000
 Why?
Double-Blind Method
1
1993
2062
0.000
 Why?
Melanocyte-Stimulating Hormones
1
1985
3
0.000
 Why?
Lithium
1
1985
40
0.000
 Why?
Postoperative Complications
1
1996
2970
0.000
 Why?
Brassica
1
1983
5
0.000
 Why?
Spain
1
1983
50
0.000
 Why?
Antigen-Antibody Complex
1
1983
69
0.000
 Why?
Drug Synergism
1
1984
354
0.000
 Why?
Syndrome
1
1983
381
0.000
 Why?
In Vitro Techniques
1
1984
1048
0.000
 Why?
Sheep
1
1984
876
0.000
 Why?
Animals
1
1984
38030
0.000
 Why?
Gaspar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (490) concept(s)
_
Co-Authors Expand Description
See all (35) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)